Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

NCT07631208 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

Interventions

DRUG: Teclistamab(SC)

Sponsor

Assistance Publique - Hôpitaux de Paris